Compare WD & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WD | ANAB |
|---|---|---|
| Founded | 1937 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2010 | 2015 |
| Metric | WD | ANAB |
|---|---|---|
| Price | $40.84 | $54.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $76.00 | $71.67 |
| AVG Volume (30 Days) | 389.0K | ★ 403.8K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $1,234,306,000.00 | $234,603,000.00 |
| Revenue This Year | $20.60 | N/A |
| Revenue Next Year | $7.79 | $52.14 |
| P/E Ratio | $75.22 | ★ N/A |
| Revenue Growth | 8.99 | ★ 157.01 |
| 52 Week Low | $39.01 | $17.11 |
| 52 Week High | $90.00 | $73.30 |
| Indicator | WD | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 43.30 |
| Support Level | $39.01 | $53.46 |
| Resistance Level | $52.37 | $57.70 |
| Average True Range (ATR) | 1.22 | 2.42 |
| MACD | 0.39 | -0.21 |
| Stochastic Oscillator | 30.10 | 13.88 |
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).